Eli Lilly and Company (LLY) Competitors

Amgen (NASDAQ:AMGN) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Which has more risk and volatility, AMGN or LLY?

Amgen has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.

Does the media refer more to AMGN or LLY?

In the previous week, Eli Lilly and Company had 105 more articles in the media than Amgen. MarketBeat recorded 154 mentions for Eli Lilly and Company and 49 mentions for Amgen. Amgen's average media sentiment score of 1.42 beat Eli Lilly and Company's score of 1.34 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	45 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eli Lilly and Company	113 Very Positive mention(s)	19 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Is AMGN or LLY a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.8%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company pays out 48.8% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years and Eli Lilly and Company has increased its dividend for 11 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Do analysts prefer AMGN or LLY?

Amgen currently has a consensus price target of $307.82, suggesting a potential upside of 2.58%. Eli Lilly and Company has a consensus price target of $1,012.22, suggesting a potential upside of 27.76%. Given Eli Lilly and Company's stronger consensus rating and higher probable upside, analysts clearly believe Eli Lilly and Company is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	12 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.35
Eli Lilly and Company	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.75

Do insiders and institutionals have more ownership in AMGN or LLY?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.8% of Amgen shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Is AMGN or LLY more profitable?

Eli Lilly and Company has a net margin of 22.67% compared to Amgen's net margin of 17.39%. Amgen's return on equity of 176.11% beat Eli Lilly and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	17.39%	176.11%	12.39%
Eli Lilly and Company	22.67%	85.51%	15.74%

Which has better earnings and valuation, AMGN or LLY?

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$33.42B	4.83	$4.09B	$10.96	27.38
Eli Lilly and Company	$45.04B	16.67	$10.59B	$12.29	64.47

Summary

Eli Lilly and Company beats Amgen on 13 of the 20 factors compared between the two stocks.